Tim Ravenscroft, Boro Dropulic, Mauro Ferrari, Thomas Beier, Richard Pfenniger, David Eichler

Jan 31, 2008

Premium

Lentigen has appointed Tim Ravenscroft as its CEO, replacing company founder Boro Dropulic, who continues to serve as president and CSO.

Before joining Lenitgen, Ravenscroft was president of Bristol-Myers Squibb Medical Imaging. He has also held various management positions at Dupont Pharmaceutical and Glaxo Wellcome.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

12

Featured Webinar

GenomeWeb/ABRF 2017 Webinar Series: Next-Generation CRISPR: New Tools for Efficient Genome Engineering

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.

Main menu